PI3K p110β isoform synergizes with JNK in the regulation of glioblastoma cell proliferation and migration through Akt and FAK inhibition

Integrated analysis of genome-wide DNA methylation, gene expression and protein expression profiles in molecular subtypes of WHO II-IV gliomas

(2015) Zhi-Liang Wang et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells

(2015) Genevieve L. Weber et al.   Oncotarget

BYL719, a new α-specific PI3K inhibitor: Single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma

(2014) Bérengère Gobin et al.   INTERNATIONAL JOURNAL OF CANCER

Role of c-Met/Phosphatidylinositol 3-Kinase (PI3k)/Akt Signaling in Hepatocyte Growth Factor (HGF)-mediated Lamellipodia Formation, Reactive Oxygen Species (ROS) Generation, and Motility of Lung Endothelial Cells

(2014) Peter V. Usatyuk et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models

(2014) Yiqing Qu et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Targeting Class IA PI3K Isoforms Selectively Impairs Cell Growth, Survival, and Migration in Glioblastoma

(2014) Katrin Höland et al.   PLoS One

Targeted inhibition of phosphatidyl inositol-3-kinase p110β, but not p110α, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers

(2013) Ju-yeon Jeong et al.   APOPTOSIS

P110 -mediated constitutive PI3K signaling limits the efficacy of p110 -selective inhibition in mantle cell lymphoma, particularly with multiple relapse

(2013) S. Iyengar et al.   BLOOD

Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110  Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast Cancers

(2013) J. T. Garrett et al.   CANCER RESEARCH

Combined inhibition of the phosphoinosityl-3-kinase (PI3Kinase) P110δ subunit and mitogen-extracellular activated protein kinase (MEKinase) shows synergistic cytotoxicity against human acute myeloid leukemia progenitors

(2013) Yan Xing et al.   LEUKEMIA RESEARCH

Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment

(2012) Irene Brana et al.   BMC Medicine

The p110  and p110  isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis

(2012) T. Utermark et al.   GENES & DEVELOPMENT

Dual blockade of lipid and cyclin-dependent kinases induces synthetic lethality in malignant glioma

(2012) C. K. Cheng et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types

(2011) Stephen Jamieson et al.   BIOCHEMICAL JOURNAL

The catalytic phosphoinositol 3-kinase isoform p110δ is required for glioma cell migration and invasion

(2011) Sze Ki Luk et al.   EUROPEAN JOURNAL OF CANCER

Phosphoinositide 3-kinase signaling pathway mediated by p110α regulates invadopodia formation

(2011) Hideki Yamaguchi et al.   JOURNAL OF CELL BIOLOGY

FAK phosphorylation at Tyr-925 regulates cross-talk between focal adhesion turnover and cell protrusion

(2011) Therese B. Deramaudt et al.   MOLECULAR BIOLOGY OF THE CELL

Zyxin phosphorylation at serine 142 modulates the zyxin head–tail interaction to alter cell–cell adhesion

(2010) Greg S. Call et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

CAL-101, a p110  selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

(2010) B. J. Lannutti et al.   BLOOD

Isoform-Specific Phosphoinositide 3-Kinase Inhibitors Exert Distinct Effects in Solid Tumors

(2010) K. A. Edgar et al.   CANCER RESEARCH

Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method

(2010) T.-C. Chou   CANCER RESEARCH

Zyxin-mediated Actin Assembly Is Required for Efficient Wound Closure

(2010) Thuc Nghi Nguyen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

PTEN restoration and PIK3CB knockdown synergistically suppress glioblastoma growth in vitro and in xenografts

(2010) Hongbo Chen et al.   JOURNAL OF NEURO-ONCOLOGY

Epidermal Growth Factor Receptor and PTEN Modulate Tissue Factor Expression in Glioblastoma through JunD/Activator Protein-1 Transcriptional Activity

(2009) Y. Rong et al.   CANCER RESEARCH

PI3K p110α and p110β have differential effects on Akt activation and protection against oxidative stress-induced apoptosis in myoblasts

(2009) R W Matheny et al.   CELL DEATH AND DIFFERENTIATION

c-Jun Regulates Phosphoinositide-dependent Kinase 1 Transcription

(2009) Pablo Lopez-Bergami et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Expression of phospho-ERK1/2 and PI3-K in benign and malignant gallbladder lesions and its clinical and pathological correlations

(2009) Qinglong Li et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Targeting the Phosphoinositide 3-Kinase Isoform p110  Impairs Growth and Survival in Neuroblastoma Cells

(2008) D. Boller et al.   CLINICAL CANCER RESEARCH

Targeting the PI3K p110  Isoform Inhibits Medulloblastoma Proliferation, Chemoresistance, and Migration

(2008) A. S. Guerreiro et al.   CLINICAL CANCER RESEARCH

Constitutive activation of c-Jun N-terminal kinase correlates with histologic grade and EGFR expression in diffuse gliomas

(2008) Jian Yi Li et al.   JOURNAL OF NEURO-ONCOLOGY

The p110  isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110 

(2008) J. Guillermet-Guibert et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA